<DOC>
	<DOCNO>NCT03004365</DOCNO>
	<brief_summary>The purpose single-blind study evaluate whether C16G2 Varnish administer multiple dos effectively kill bacteria oral cavity cause dental caries .</brief_summary>
	<brief_title>A Study Evaluate Safety Microbiology C16G2 Varnish Administered Multiple Doses Dental Subjects</brief_title>
	<detailed_description>A single-blind , randomize , placebo-controlled Phase 2 study evaluate safety oral microbiology C16G2 Varnish application male female dental subject 12-75 year age . This multi-center study evaluate multiple study drug administration C16G2 Varnish Placebo . The study enroll subject three study arm . Up 33 subject receive multiple dos study drug apply small brush typically use dental varnish administration . Subjects enrol 8:3 ratio . The Sponsor perform unblinded microbiology review ongoing basis determine whether enroll additional 11 subject next dose cohort terminate enrollment base microbiology data .</detailed_description>
	<mesh_term>Dental Caries</mesh_term>
	<criteria>1 . Males female , 1275 year age 2 . Adults subject provide write informed consent adolescent subject give write verbal assent , appropriate , parent ( ) legal guardian ( ) give write informed consent 3 . Female subject childbearing potential must agree use one follow form contraception screen last study visit : hormonal ( oral , implant , injection ) begin &gt; 30 day prior screen ; barrier ( condom , diaphragm , cervical cap spermicide ) ; intrauterine device ( IUD ) . Acceptable contraceptive option may also include abstinence , relationship sex partner partner vasectomy least six ( 6 ) month prior screen visit 4 . Negative urine pregnancy test female childbearing potential ( past menarche ) 5 . Male subject sexual activity age : willing use contraception abstain sexual activity begin first exposure study drug continue discharge study due completion Early Termination 6 . Healthy , determine Investigator ( consultation Medical Monitor , need ) , base medical dental history , concurrent illness , laboratory result , concomitant medication , oral cavity assessment , target physical examination ( general , extraoral , head neck ) Screening . Note : Subjects stable dose medication may eligible screen assessed medical monitor casebycase basis . 7 . Have minimum 12 bicuspid molar minimum 8 molar bicuspid NOT restoration , crown sealant 8 . Demonstrated ability expectorate â‰¥2 mL stimulate saliva 5 minute 9 . Have salivary S. mutans 1.0 x 105 CFUs/mL great Screening use MSB agar plat 10 . Willing refrain use nonstudy dentifrice nonstudy oral care product ( oral care rinse , fluoride product , etc . ) study 11 . Willing postpone elective dental procedure ( e.g. , dental cleaning ) Screening final posttreatment visit ( End Study Early Termination ) 12 . Willing able comply oral hygiene diet instruction 13 . Able communicate Investigator/study center personnel , understand comply study requirement , willing return protocolspecified visit appoint time 1 . Advanced periodontal disease 2 . Active caries lesion ( ) within 30 day prior study drug administration ( confirmed comprehensive caries examination include standard radiograph ) . Subjects present insipient , noncavitated lesion ( ) exclude . Note : If radiograph deem appropriate study take within 6 month prior Screening visit , may use determine eligibility require repeat Screening 3 . Partially erupt teeth entire crown erupt operculum present 4 . Medical condition ( e.g. , artificial heart valve , history infective endocarditis , cardiac transplant valvular dysfunction , congenital heart disease total joint replacement ) antibiotic recommend prior dental visit and/or procedure 5 . Pathologic lesion oral cavity ( suspicious confirm ) 6 . Full dentures permanent orthodontic appliance , e.g. , brace , buccal lingual bracket . Note : Partial denture , removable retainer night guard exclude , provide clean regularly throughout duration study 7 . Use systemic antibiotic , topical oral antibiotic , use drug , opinion Investigator could influence study outcome , begin 30 day prior Screening end study participation 8 . Medical history indicate woman pregnant , breastfeeding/lactating positive urine pregnancy test 9 . Participation clinical trial receipt nonFDA approve therapy within 30 day prior study drug administration ( depend specific , participation observational study necessarily exclude ) 10 . Presence condition concurrent illness , opinion Investigator , would compromise normal immune function ( e.g. , diabetes , rheumatoid arthritis , lupus , liver disease , organ transplant , etc . ) , interfere use study dentifrice oral care product , interfere ability comply study requirement , jeopardize safety subject validity study result</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>